Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.

ABSTRACT:

Background

Delta-like ligand 3 (DLL3) is a therapeutic target in small-cell lung cancer (SCLC). However, how DLL3 expression status affects the tumor microenvironment (TME) and clinical outcomes in SCLC remains unclear.

Methods

This retrospective study included patients with postoperative limited-stage (LS)-SCLC and extensive-stage (ES)-SCLC treated with platinum and etoposide (PE) plus anti-programmed cell death ligand 1 (PD-L1) antibody. We investigated the relationship of DLL3 expression with TME, mutation status, tumor neoantigens, and immunochemotherapy.

Results

In the LS-SCLC cohort (n = 59), whole-exome sequencing revealed that DLL3_High cases had significantly more neoantigens (P = 0.004) and a significantly higher rate of the signature SBS4 associat

SUBMITTER: Shirasawa M 

PROVIDER: S-EPMC10703835 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature